Vertex Pharmaceuticals
Q1 2023 Earnings Call
May 01, 2023, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day and welcome to the Vertex Pharmaceuticals first-quarter 2023 conference call. All participants will be in a listen-only mode. [Operator instructions] Please note, this event is being recorded. I would now like to turn the conference over to Ms.
Susie Lisa. Please go ahead.
Susie Lisa -- Senior Vice President, Investor Relations
Good evening, all. My name is Susie Lisa, and as the senior vice president of investor relations, it is my pleasure to welcome you to our first-quarter 2023 financial results conference call. On tonight's call making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and president; Stuart Arbuckle, chief operating officer; and Charlie Wagner, chief financial officer.
We recommend that you access the webcast slides as you listen to this call. The call is being recorded and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation, those regarding Vertex's marketed cystic fibrosis medicines, our pipeline, and Vertex's future financial performance are based on management's current assumptions.
Actual outcomes and events could differ materially. I would also note that select financial results and guidance that we will review on the call this evening are presented on a non-GAAP basis. In addition, the impact of foreign exchange is presented inclusive of our foreign exchange risk management program. I will now turn the call over to Reshma.
Reshma Kewalramani -- President and Chief Executive Officer
Thanks, Susie. Good evening, all, and thank you for joining us on the call today. We're pleased to have opened with a strong start to 2023 as first-quarter global CF product revenues grew 13% versus the first quarter of 2022. In addition, we completed the exa-cel U.S.
rolling BLA submissions for sickle cell disease and beta thalassemia and secured U.S. approval for Trikafta in patients 2 to 5 years of age. Now is an especially exciting time at Vertex because, within our five launches in five years, or five and five goal, we see multiple programs with near-term launch potential including exa-cel in sickle cell disease and transfusion-dependent beta thalassemia, the Vanzacaftor triple in CF and VX-548 for acute pain. In total, we now have programs in eight disease areas in mid- and late-stage development, six of which are past the proof-of-concept stage as depicted on Slide 5.